Indian pharmaceutical company Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) (BSE:524715) confirmed on Monday that it has completed its merger with Taro Pharmaceutical Industries Ltd (NYSE:TARO), an Israeli research-based pharmaceutical company.
Sun acquired all outstanding Taro shares, making Taro a wholly-owned subsidiary. This strengthens Sun Pharma's position in the competitive generics market by combining their strengths and capabilities.
Sun has been Taro's majority shareholder since 2010.
DifGen Pharmaceuticals' Fluorometholone Ophthalmic Suspension, 0.1% receives FDA approval
Viatris names new chief legal officer
Alvotech signs biosimilar supply and commercialisation deals with Sandoz
InSysBio agrees new collaborative project with BeOne Medicines
Apiject to open new generic injectable drug manufacturing facility in Apex, NC
Bionpharma and STEERLife's Etravirine tablets approved by US FDA
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Accord Healthcare launches Clomiphene tablets in US market
Zentiva receives ESG Transparency Award 2025
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval